ASIA-PACIFIC IMMUNOGLOBULIN MARKET 2022-2028

Lifesciences | Diagnostic & Biotechnology

ASIA-PACIFIC IMMUNOGLOBULIN MARKET 2022-2028

Market by Type, Delivery Mode, Application, End-user, Sales Channel, and Country Outlook | Forecast 2022-2028

Request For Customization

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

As per Triton Market Research’s report, the immunoglobulin market in the Asia-Pacific is likely to grow with a CAGR of 7.11% in the forecasting years 2022-2028.


Report scope can be customized per your requirements. Request For Customization

The countries analyzed in this region include:

•         India

•         China

•         Japan

•         South Korea

•         Australia & New Zealand

•         ASEAN Countries

•         Rest of Asia-Pacific

The rapid increase in the geriatric population, increasing prevalence of various diseases, and enhanced focus on research & development are a few factors boosting the demand for immunoglobulin across various countries in this region. In addition, the contribution from several market players in launching advanced and innovative immunoglobulin products is also fostering the market’s growth.

South Korea is witnessing a rapid increase in the geriatric population, which is expected to bolster the growth of the immunoglobulin market. Further, according to statistics, the geriatric population of the country comprised 3.51 million males and 4.61 million females in 2020, and this number is expected to reach 8.98 million males and 9.84 million females by 2060. The rise in the elderly population results in an increased incidence of immunodeficiency diseases and the severity of various infections. This is expected to accelerate the demand for immunoglobulin products.

Also, multiple factors, such as reduced levels of thymic hormones, thymic involution, and an increase in the number of immature T lymphocytes, are responsible for altered cells in the population. Thus, to treat such conditions, the adoption of immunoglobulin products and therapies is on the rise, which is expected to boost the market’s growth in the near future.

In Japan, the increasing usage of immunoglobulin for the prevention of chronic inflammatory demyelination polyneuropathy progression has presented an upward trend for the market. Top players are developing new and advanced products to treat multiple diseases and offer therapeutic benefits to patients, thus contributing to the growth of the immunoglobulin market in the country.

Subcutaneous immunoglobulin is the human immunoglobulin for subcutaneous use, an injection needle inserted under the patient’s skin. This delivery mode type is a solution of human plasma proteins and immunoglobulin G antibodies. Generally, these are prepared from large pools of human plasma and consist of typical immunoglobulin G antibodies. In recent years, the administration of immunoglobulin through the subcutaneous route has become significantly popular. Besides, this further helps treat autoimmune neurological conditions such as multifocal motor neuropathy.

The studied report assesses the market’s growth based on the type, delivery mode, application, end-user, and sales channel. Here, the delivery mode segment comprises intravenous, subcutaneous, and intramuscular.

The leading companies considered in the immunoglobulin market include Bio Products Laboratory, Shanghai RAAS Blood Products Co Ltd, Kedrion Biopharma, Kamada Ltd, Sanquin Plasma Products BV, LFB Group, Takeda Pharmaceutical Company Limited, and Octapharma AG.

China Biologic Products Inc is a leading biopharmaceutical company that offers a wide range of plasma-derived products. The company’s core business includes developing, manufacturing, and selling plasma-derived & other biopharmaceutical products. The company’s product portfolio comprises 10 plasma-derived products with more than 20 specifications in human immunoglobulin, human albumin, and human coagulation factors. Moreover, being a leader in plasma-derived products, the company possesses advanced technology and world-class R&D capabilities. It was founded in 2002. China Biologic Products Inc is headquartered in Chaoyang District, Beijing.

 

Key deliverables of the report:

      Market CAGR during the forecasting years 2022-2028

      Detailed data highlighting key insights, industry components, and market strategies

   Comprehensive information and estimation of the immunoglobulin market revenue growth in Asia-Pacific and its influence on the parent market

      In-depth study of forthcoming trends in consumer behavioral patterns

      A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces Model

  A wide-ranging study of factors that will challenge the Asia-Pacific immunoglobulin market’s growth during the upcoming years

Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. ASIA-PACIFIC IMMUNOGLOBULIN MARKET – SUMMARY

2. INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON THE IMMUNOGLOBULIN MARKET

2.2. KEY INSIGHTS

2.2.1. DEVELOPMENT OF NEW PURIFICATION METHODS

2.2.2. INCREASING PREFERENCE FOR PERSONALIZED MEDICINES

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTES

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR SCORECARD

2.6. KEY MARKET STRATEGIES

2.6.1. PRODUCT LAUNCHES & DEVELOPMENTS

2.6.2. PARTNERSHIPS & AGREEMENTS

2.7. MARKET DRIVERS

2.7.1. GROWTH IN THE GERIATRIC POPULATION

2.7.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

2.7.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

2.8. MARKET CHALLENGES

2.8.1. HIGH COST OF THERAPY

2.8.2. HIGH RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN

2.9. MARKET OPPORTUNITIES

2.9.1. INCREASING ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS

2.9.2. GROWING CLINICAL TRIALS

3. ASIA-PACIFIC IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE

3.1. IGG

3.2. IGA

3.3. IGM

3.4. IGE

3.5. IGD

4. ASIA-PACIFIC IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE

4.1. INTRAVENOUS

4.2. SUBCUTANEOUS

4.3. INTRAMUSCULAR

5. ASIA-PACIFIC IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION

5.1. HYPOGAMMA GLOBULINEMIA

5.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

5.3. PRIMARY IMMUNODEFICIENCY DISEASES

5.4. MYASTHENIA GRAVIS

5.5. MULTIFOCAL MOTOR NEUROPATHY

5.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

5.7. INFLAMMATORY MYOPATHIES

5.8. SPECIFIC ANTIBODY DEFICIENCY

5.9. GUILLAIN-BARRE SYNDROME

5.10. OTHER APPLICATIONS

6. ASIA-PACIFIC IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER

6.1. HOSPITALS & CLINICS

6.2. HOMECARE

7. ASIA-PACIFIC IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL

7.1. HOSPITAL PHARMACY

7.2. SPECIALTY PHARMACY

7.3. OTHER SALES CHANNELS

8. ASIA-PACIFIC IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK

8.1. CHINA

8.2. JAPAN

8.3. INDIA

8.4. SOUTH KOREA

8.5. ASEAN COUNTRIES

8.6. AUSTRALIA & NEW ZEALAND

8.7. REST OF ASIA-PACIFIC

9. COMPETITIVE LANDSCAPE

9.1. BIOTEST AG

9.2. CHINA BIOLOGIC PRODUCTS INC

9.3. GRIFOLS SA

9.4. LFB GROUP

9.5. CSL BEHRING

9.6. KEDRION BIOPHARMA

9.7. OCTAPHARMA AG

9.8. TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.9. BIO PRODUCTS LABORATORY

9.10. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

9.11. PFIZER INC

9.12. SANQUIN PLASMA PRODUCTS BV

9.13. ADMA BIOLOGICS

9.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

9.15. KAMADA LTD

10. RESEARCH METHODOLOGY & SCOPE

10.1. RESEARCH SCOPE & DELIVERABLES

10.2. SOURCES OF DATA

10.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 4: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 5: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 6: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 7: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 8: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

List of Figures

FIGURE 1: MARKET ATTRACTIVENESS INDEX

FIGURE 2: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)

FIGURE 3: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)

FIGURE 4: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)

FIGURE 5: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)

FIGURE 6: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)

FIGURE 7: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)

FIGURE 8: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)

FIGURE 9: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)

FIGURE 10: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)

FIGURE 12: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)

FIGURE 13: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)

FIGURE 14: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)

FIGURE 17: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 18: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028 (IN $ MILLION)

FIGURE 19: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)

FIGURE 20: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $ MILLION)

FIGURE 21: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)

FIGURE 22: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)

FIGURE 23: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)

FIGURE 24: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)

FIGURE 25: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)

FIGURE 26: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)

FIGURE 27: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 28: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 29: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)

FIGURE 30: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)

FIGURE 31: CHINA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 32: JAPAN IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 33: INDIA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 34: SOUTH KOREA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 35: ASEAN COUNTRIES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 36: AUSTRALIA & NEW ZEALAND IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 37: REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying